[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 38 of about 38
1. Breslow NE, Ou SS, Beckwith JB, Haase GM, Kalapurakal JA, Ritchey ML, Shamberger RC, Thomas PR, D'Angio GJ, Green DM: Doxorubicin for favorable histology, Stage II-III Wilms tumor: results from the National Wilms Tumor Studies. Cancer; 2004 Sep 1;101(5):1072-80
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Doxorubicin for favorable histology, Stage II-III Wilms tumor: results from the National Wilms Tumor Studies.
  • BACKGROUND: After randomized trials in the 1980s, doxorubicin (DOX) was added to dactinomycin plus vincristine as standard chemotherapy for patients who had Stage III Wilms tumor (WT) of favorable histology (FH).
  • Double-agent chemotherapy was retained for patients with Stage II disease.
  • METHODS: The relative risks (RR) (DOX vs. no DOX) of disease recurrence and mortality were estimated for patients with Stage II-III/FH WT who were enrolled in the third and fourth National Wilms Tumor Studies (NWTS-3 and NWTS-4).
  • RESULTS: No statistically significant effects of DOX were found for patients with Stage II tumors.
  • For patients with Stage III tumors, the 8 year recurrence-free survival (RFS) and overall survival (OS) rates for randomized patients on NWTS-3 were 84% and 89%, respectively, for patients who received DOX (n = 130) and 74% and 83%, respectively, for patients who did not receive DOX (n = 118).
  • Including all patients with Stage III disease who received DOX (n = 678) and did not receive DOX (n = 138), the RRs of recurrence were 0.47 (P = 0.007) and 0.40 (P = 0.011), and local recurrence respectively, after adjustment for radiation therapy (RT) dose, whereas the RR of mortality adjusted for RT and study was 0.68 (P = 0.17).
  • The 20-year risk of CHF after primary DOX treatment on NWTS-3 and NWTS-4 was 1.2%.
  • CONCLUSIONS: The inclusion of data from nonrandomized patients yielded estimates of DOX treatment effects for Stage III/FH WT that were stronger, albeit more susceptible to bias, than reported previously.
  • Despite a lower reported risk of CHF, conclusive evidence that frontline therapy with DOX definitively improves survival remains elusive.

  • MedlinePlus Health Information. consumer health - Heart Failure.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • MedlinePlus Health Information. consumer health - Wilms Tumor.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. DACTINOMYCIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2004 American Cancer Society.
  • (PMID = 15329918.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA054498; United States / NCI NIH HHS / CA / CA 42326; United States / NCI NIH HHS / CA / CA 54498
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 1CC1JFE158 / Dactinomycin; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin
  •  go-up   go-down


2. Cowey CL, Amin C, Pruthi RS, Wallen EM, Nielsen ME, Grigson G, Watkins C, Nance KV, Crane J, Jalkut M, Moore DT, Kim WY, Godley PA, Whang YE, Fielding JR, Rathmell WK: Neoadjuvant clinical trial with sorafenib for patients with stage II or higher renal cell carcinoma. J Clin Oncol; 2010 Mar 20;28(9):1502-7
Hazardous Substances Data Bank. NICOTINAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neoadjuvant clinical trial with sorafenib for patients with stage II or higher renal cell carcinoma.
  • PURPOSE: The multitargeted tyrosine kinase inhibitor sorafenib is used for the treatment of advanced-stage renal cell carcinoma.
  • PATIENTS AND METHODS: Thirty patients with clinical stage II or higher renal masses, selected based on their candidacy for nephrectomy, underwent preoperative treatment with sorafenib.
  • After a course of sorafenib therapy (median duration, 33 days), a decrease in primary tumor size (median, 9.6%) and radiographic evidence of loss of intratumoral enhancement, quantified using a methodology similar to Choi criteria (median, 13%), was also observed.
  • According to Response Evaluation Criteria in Solid Tumors, of the 28 patients evaluable for response, two patients had a partial response and 26 had stable disease, with no patients progressing on therapy.
  • Toxicities from sorafenib were similar to that expected with this class of medication.
  • CONCLUSION: The administration of preoperative sorafenib therapy can impact the size and density of the primary tumor and appears safe and feasible.
  • Further studies are required to determine if preoperative systemic therapy improves outcomes in patients undergoing nephrectomy for renal cell carcinoma.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Benzenesulfonates / administration & dosage. Carcinoma, Renal Cell / drug therapy. Kidney Neoplasms / drug therapy. Neoadjuvant Therapy. Pyridines / administration & dosage
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Feasibility Studies. Female. Humans. Male. Middle Aged. Neoplasm Staging. Niacinamide / analogs & derivatives. Phenylurea Compounds. Pilot Projects. Prospective Studies. Treatment Outcome. Young Adult

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20159822.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA121781
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzenesulfonates; 0 / Phenylurea Compounds; 0 / Pyridines; 25X51I8RD4 / Niacinamide; 9ZOQ3TZI87 / sorafenib
  • [Other-IDs] NLM/ PMC4525128
  •  go-up   go-down


3. Derleth C, Mayer IA: Antiangiogenic therapies in early-stage breast cancer. Clin Breast Cancer; 2010;10 Suppl 1:E23-31
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Antiangiogenic therapies in early-stage breast cancer.
  • Angiogenesis, which is crucial for the growth and spread of cancer cells, has become an important target for antineoplastic therapies in a variety of malignant tumors.
  • Vascular endothelial growth factor and its receptor promote formation of new blood vessels in tumors.
  • Several drugs, most notably the monoclonal antibody bevacizumab, have been developed to inhibit this process.
  • Clinical trials utilizing bevacizumab and other antiangiogenic drugs in metastatic breast cancer have demonstrated enhanced response rates and prolonged progression-free survival, though no overall survival benefit has been seen.
  • Trials are now under way exploring the use of antiangiogenic agents in patients with early stage breast cancer.
  • We performed a comprehensive review of the published literature (English language), US National Institutes of Health clinical trials registry (ClinicalTrials.gov), and established cooperative groups that revealed approximately 75 clinical trials, completed or ongoing, utilizing antiangiogenic drugs in early-stage breast cancer.
  • A number of phase II trials in the neoadjuvant setting have reported preliminary results suggesting response rates similar to those seen with traditional anthracycline-plus-taxane combination regimens.
  • This number is significantly higher in patients receiving antiangiogenic drugs when compared with controls.
  • While we eagerly await completion and results of this impressive portfolio of studies in early breast cancer with antiangiogenic agents, there is an urgent need for a more rational patient/antiangiogenic therapy selection with greater insight into predictive factors for toxicities, therapy efficacy, and clinical benefit.

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2007 Jul 20;25(21):3045-54 [17634482.001]
  • [Cites] J Natl Cancer Inst. 2007 Aug 15;99(16):1232-9 [17686822.001]
  • [Cites] N Engl J Med. 2007 Oct 11;357(15):1547-9 [17928605.001]
  • [Cites] N Engl J Med. 2007 Dec 27;357(26):2666-76 [18160686.001]
  • [Cites] J Clin Oncol. 2008 Apr 10;26(11):1810-6 [18347007.001]
  • [Cites] BMC Cancer. 2008;8:88 [18384688.001]
  • [Cites] J Clin Oncol. 2008 Jun 10;26(17):2839-45 [18539962.001]
  • [Cites] Lancet. 2008 Jun 21;371(9630):2101-8 [18514303.001]
  • [Cites] Clin Cancer Res. 2006 Mar 1;12(5):1570-6 [16533783.001]
  • [Cites] Clin Cancer Res. 2006 May 15;12(10):3124-9 [16707611.001]
  • [Cites] Am J Kidney Dis. 2007 Feb;49(2):186-93 [17261421.001]
  • [Cites] Clin Cancer Res. 2007 Apr 15;13(8):2329-34 [17438091.001]
  • [Cites] Nat Med. 1999 Dec;5(12):1359-64 [10581076.001]
  • [Cites] Oncologist. 2000;5 Suppl 1:37-44 [10804090.001]
  • [Cites] Crit Rev Oncol Hematol. 2001 Feb;37(2):97-114 [11166583.001]
  • [Cites] J Clin Oncol. 2001 Feb 1;19(3):843-50 [11157038.001]
  • [Cites] Cancer Res. 2001 Jul 15;61(14):5407-14 [11454684.001]
  • [Cites] Am J Pathol. 2002 Jan;160(1):381-2; author reply 382-3 [11786431.001]
  • [Cites] J Clin Oncol. 2002 Mar 15;20(6):1456-66 [11896092.001]
  • [Cites] Cancer. 2002 Jun 1;94(11):2855-61 [12115372.001]
  • [Cites] Semin Oncol. 2002 Jun;29(3 Suppl 11):29-37 [12138395.001]
  • [Cites] Reproduction. 2003 Mar;125(3):337-46 [12611597.001]
  • [Cites] Nat Med. 2003 Jun;9(6):669-76 [12778165.001]
  • [Cites] Nat Med. 2003 Jun;9(6):713-25 [12778170.001]
  • [Cites] J Clin Oncol. 2003 Jul 1;21(13):2600-8 [12829681.001]
  • [Cites] N Engl J Med. 2003 Jul 31;349(5):427-34 [12890841.001]
  • [Cites] Semin Oncol. 2003 Oct;30(5 Suppl 16):117-24 [14613032.001]
  • [Cites] J Clin Oncol. 2003 Nov 15;21(22):4165-74 [14559892.001]
  • [Cites] Eur J Cancer. 2004 Jan;40(1):33-42 [14687787.001]
  • [Cites] Clin Cancer Res. 2004 Mar 1;10(5):1706-16 [15014023.001]
  • [Cites] Clin Cancer Res. 2004 May 15;10(10):3249-61 [15161677.001]
  • [Cites] N Engl J Med. 2004 Jun 3;350(23):2335-42 [15175435.001]
  • [Cites] Nature. 1993 Apr 29;362(6423):841-4 [7683111.001]
  • [Cites] Cell. 1994 Oct 21;79(2):185-8 [7525076.001]
  • [Cites] Hum Pathol. 1995 Jan;26(1):86-91 [7821921.001]
  • [Cites] J Clin Invest. 1995 Apr;95(4):1789-97 [7535799.001]
  • [Cites] Breast Cancer Res Treat. 1995;36(2):103-7 [8534859.001]
  • [Cites] Endocr Rev. 1997 Feb;18(1):4-25 [9034784.001]
  • [Cites] Cancer Res. 1997 Mar 1;57(5):963-9 [9041202.001]
  • [Cites] J Clin Oncol. 1997 Jul;15(7):2483-93 [9215816.001]
  • [Cites] Am J Pathol. 1997 Dec;151(6):1523-30 [9403702.001]
  • [Cites] Cancer J Sci Am. 1999 Mar-Apr;5(2):101-11 [10198732.001]
  • [Cites] Kidney Int. 1999 Sep;56(3):794-814 [10469350.001]
  • [Cites] J Clin Oncol. 2005 Feb 1;23(4):792-9 [15681523.001]
  • [Cites] J Clin Oncol. 2005 Mar 10;23(8):1782-90 [15755986.001]
  • [Cites] Clin Cancer Res. 2005 May 1;11(9):3369-76 [15867237.001]
  • [Cites] Mol Endocrinol. 2005 Aug;19(8):2006-19 [15774498.001]
  • [Cites] Br J Cancer. 2005 Oct 17;93(8):876-83 [16222321.001]
  • [Cites] J Clin Oncol. 2006 Feb 10;24(5):769-77 [16391297.001]
  • [Cites] J Clin Oncol. 2007 Jun 10;25(17):2369-76 [17557949.001]
  • [Cites] Nat Rev Cancer. 2008 Aug;8(8):592-603 [18650835.001]
  • [Cites] Exp Biol Med (Maywood). 2008 Aug;233(8):1013-20 [18480415.001]
  • [Cites] Clin Cancer Res. 2008 Nov 15;14(22):7526-34 [19010871.001]
  • [Cites] JAMA. 2008 Nov 19;300(19):2277-85 [19017914.001]
  • [Cites] J Clin Oncol. 2009 Jan 1;27(1):11-5 [19047293.001]
  • [Cites] Ann Oncol. 2009 Feb;20(2):227-30 [18842611.001]
  • [Cites] Anticancer Drugs. 2009 Mar;20(3):197-203 [19182679.001]
  • [Cites] Ann Oncol. 2009 May;20(5):967-70 [19403940.001]
  • [Cites] Cancer Res. 2009 Jun 1;69(11):4716-23 [19435899.001]
  • [Cites] Clin Cancer Res. 2009 Jun 15;15(12):4220-7 [19509175.001]
  • [Cites] J Clin Oncol. 2009 Jul 10;27(20):3385-90 [19414665.001]
  • [Cites] J Clin Oncol. 2009 Jul 20;27(21):3557-65 [19546406.001]
  • [Cites] Clin Cancer Res. 2009 Sep 1;15(17):5297-302 [19706811.001]
  • [Cites] Anticancer Drugs. 2009 Aug;20(7):616-24 [19739318.001]
  • [Cites] Eur J Surg Oncol. 2009 Oct;35(10):1048-54 [19250795.001]
  • [Cites] Mol Cancer Ther. 2009 Nov;8(11):2983-91 [19887543.001]
  • [Cites] J Clin Oncol. 2010 Feb 1;28(4):628-33 [19841327.001]
  • [Cites] J Clin Oncol. 2011 Apr 1;29(10):1252-60 [21383283.001]
  • [Cites] Clin Breast Cancer. 2011 Aug;11(4):228-34 [21684812.001]
  • [Cites] Ann Oncol. 2012 Feb;23(2):331-7 [21821545.001]
  • (PMID = 20587404.001).
  • [ISSN] 1938-0666
  • [Journal-full-title] Clinical breast cancer
  • [ISO-abbreviation] Clin. Breast Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P50 CA098131; United States / NCI NIH HHS / CA / 2P50 CA098131-06
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Vascular Endothelial Growth Factor A; 2S9ZZM9Q9V / Bevacizumab; EC 2.7.10.1 / Receptors, Vascular Endothelial Growth Factor
  • [Other-IDs] NLM/ NIHMS406908; NLM/ PMC3471531
  •  go-up   go-down


Advertisement
4. Takamizawa S, Okamoto S, Bishop W, Wen J, Kimura K, Sandler A: Differential apoptosis gene expression in pediatric tumors of the kidney. J Pediatr Surg; 2000 Feb;35(2):390-5
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differential apoptosis gene expression in pediatric tumors of the kidney.
  • BACKGROUND/PURPOSE: Apoptosis, or programmed cell death, is essential in maintaining normal homeostasis of tissues.
  • This study evaluates the expression of apoptotic mRNA species in pediatric renal tumors to determine whether a pattern of differential apoptosis gene expression correlates with tumor grade and type.
  • METHODS: Twenty-five frozen tissue specimens were obtained from patients undergoing biopsy or resection of pediatric renal tumors before chemotherapy: Wilms' tumor stage II (WT-II, n = 4); Wilms' tumor stage III/IV (WT-III/IV, n = 4); clear cell sarcoma of the kidney stage III (CCSK, n = 2); rhabdoid tumor of the kidney stage III/IV (RTK, n = 4); and normal kidney (NK, n = 11).
  • RESULTS: The expression of apoptotic mRNA species varied markedly between tumors.
  • WT-II expressed greater amounts of proapoptotic receptor mRNA than CCSK or RTK. (Fas, 17.0+/-2.7% v. 2.5+/-0.5% v. 3.3+/-0.9%; P<.02; DR5, 77.0+/-8.8% v. 13.5+/-0.5% v. 27.0+/-4.8; P<.001; TNF-R, 71.3+/-17.0% v. 21.0+/-4.0% v. 29.0+/-5.0%; P<.07, respectively).
  • Surprisingly, antiapoptotic factors (e.g., bcl-2 and bcl-xl) were not overexpressed in poor prognostic tumors (CCSK, RTK) compared with those with good prognosis (WT).
  • Expression of TRAIL (a ligand for DR4 and DR5) was significantly lower in CCSK and RTK than in normal kidney (9.5+/-1.5% v. 56.1+/-10.1%; P = .01).
  • CONCLUSIONS: Proapoptotic receptors are expressed at greater levels in good prognostic tumors, and this finding is compatible with their clinical behavior.
  • Knowledge of differential apoptotic gene expression is of potential value in predicting prognosis and treating such tumors with targeted ligands.
  • [MeSH-major] Apoptosis / genetics. Gene Expression. Kidney Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10693703.001).
  • [ISSN] 0022-3468
  • [Journal-full-title] Journal of pediatric surgery
  • [ISO-abbreviation] J. Pediatr. Surg.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / HLA-DR Antigens; 0 / RNA, Messenger; 0 / Tumor Necrosis Factor-alpha
  •  go-up   go-down


5. Granzen B, Efferth T, Keller U, Beniers AJ, Mertens R, Jakse G, Füzesi L: Differential expression of the drug resistance markers DNA topoisomerase II alpha and glutathione S-transferase-pi in the histological compartments of Wilms' tumors. Anticancer Res; 2001 Jan-Feb;21(1B):771-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differential expression of the drug resistance markers DNA topoisomerase II alpha and glutathione S-transferase-pi in the histological compartments of Wilms' tumors.
  • Some patients, however, fail to respond to chemotherapy.
  • The objective of this study was to analyze the immunohistochemical distribution of two markers of cytostatic drug resistance, e.g.
  • DNA topoisomerase II alpha (Topo II alpha) and glutathione S-transferase-pi (GST-pi) in 23 Wilms' tumor patients who had undergone an operation between 1984 and 1997.
  • Eight patients had stage I disease, seven stage II, three stage III, four stage IV, and one stage V disease.
  • Five tumors showed high malignancy histology.
  • Investigations were carried out on formalin-fixed and paraffin-embedded tissue sections using the indirect immunoperoxidase method.
  • Topo II alpha was predominantly present in the epithelial components of the specimens.
  • It was more frequently found in anaplastic tumors.
  • There was no difference in the presence of Topo II alpha in the epithelial components between specimens derived from treated and untreated patients.
  • Topo II alpha was, however, less expressed in the blastemal and stromal elements of specimens after preoperative treatment.
  • While no expression of GST-pi was found in preoperatively untreated Wilms' tumors, it was present in epithelial compartments in 57% of tumors after chemotherapy.
  • In conclusion, preoperative chemotherapy led to compartment-specific alterations in the expression levels of both markers indicating a contribution to treatment response of Wilms' tumors.
  • [MeSH-major] DNA Topoisomerases, Type II / analysis. Drug Resistance, Neoplasm. Glutathione Transferase / analysis. Isoenzymes / analysis. Kidney Neoplasms / enzymology. Neoplasm Proteins / analysis. Wilms Tumor / enzymology
  • [MeSH-minor] Antigens, Neoplasm. Chemotherapy, Adjuvant. Child. Child, Preschool. Combined Modality Therapy. DNA-Binding Proteins. Epithelial Cells / enzymology. Female. Follow-Up Studies. Humans. Infant. Male. Neoplasm Staging. Neoplastic Stem Cells / enzymology. Nephrectomy. Premedication. Stromal Cells / enzymology

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • MedlinePlus Health Information. consumer health - Wilms Tumor.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Anticancer Res 2001 Jul-Aug;21(4A):2861
  • (PMID = 11299842.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / DNA-Binding Proteins; 0 / Isoenzymes; 0 / Neoplasm Proteins; EC 2.5.1.18 / Glutathione Transferase; EC 5.99.1.3 / DNA Topoisomerases, Type II; EC 5.99.1.3 / DNA topoisomerase II alpha
  •  go-up   go-down


6. Shi X, Zhu XD, Wang HM: [Effect of supporting the healthy energy and strengthening Pi principle of TCM combined with chemotherapy in treating children with solid tumors]. Zhongguo Zhong Xi Yi Jie He Za Zhi; 2007 Jun;27(6):542-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Effect of supporting the healthy energy and strengthening Pi principle of TCM combined with chemotherapy in treating children with solid tumors].
  • OBJECTIVE: To study the clinical validity in improving quality of life (QOL) of patients and alleviating adverse reaction of chemotherapy in treating children with solid tumors by Chinese herbal medicine for supporting healthy energy and strengthening Pi.
  • METHODS: A prospective cohort study was conducted in 60 children with solid tumor in stage II-IV, who were assigned to two groups, 30 in each group.
  • All children received chemotherapy and those in the observed group were given Chinese herbs according to syndrome differentiation additionally.
  • The conditions of the two groups were compared after 6-month treatment.
  • RESULTS: Compared with before treatment, the white blood cells (WBC), hemoglobin (Hb), and platelet (PLT) all increased in the observed group after treatment (P < 0.01, P < 0.01, P < 0.05), while in the control group, the WBC and Hb have no significant difference (P > 0.05) and PLT decreased (P < 0.05) after treatment.
  • Comparison between the two groups, the clinical symptom score in the observed group has significant difference after treatment (P < 0.05).
  • CONCLUSION: Chinese herbal medicine for supporting healthy energy, strengthening Pi and supplementing qi-blood is good for alleviating the adverse reaction and improving patients' peripheral blood picture in children with solid tumor undergoing chemotherapy.

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • MedlinePlus Health Information. consumer health - Wilms Tumor.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17633370.001).
  • [ISSN] 1003-5370
  • [Journal-full-title] Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chinese journal of integrated traditional and Western medicine
  • [ISO-abbreviation] Zhongguo Zhong Xi Yi Jie He Za Zhi
  • [Language] CHI
  • [Publication-type] English Abstract; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Drugs, Chinese Herbal
  •  go-up   go-down


7. Takahashi M, Yang XJ, Lavery TT, Furge KA, Williams BO, Tretiakova M, Montag A, Vogelzang NJ, Re GG, Garvin AJ, Söderhäll S, Kagawa S, Hazel-Martin D, Nordenskjold A, Teh BT: Gene expression profiling of favorable histology Wilms tumors and its correlation with clinical features. Cancer Res; 2002 Nov 15;62(22):6598-605
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gene expression profiling of favorable histology Wilms tumors and its correlation with clinical features.
  • The aims of this study were to understand the underlying molecular mechanisms of favorable histology Wilms tumors (WTs) and to classify them based on their molecular signatures.
  • A total of 267 cDNAs were significantly overexpressed at least 3-fold in all of the tumors compared with noncancerous kidney and contained known WT-related genes such as IGF II and WT1.
  • The gene with the highest expression change compared with noncancerous kidney was topoisomerase IIalpha.
  • By hierarchical clustering, there was a clear distinction between high-stage and low-stage tumors.
  • A total of 30 cDNAs were found differentially expressed between the high- and low-stage groups.
  • One of them, Stathmin 1, which is involved in the microtubule system, was highly expressed in high-stage tumors compared with the low-stage tumors.
  • The present chemotherapy regimens for WT consist mainly of topoisomerase II inhibitors (i.e., actinomycin D, doxorubicin, and etoposide) and antimicrotubule agents (i.e., vincristine and paclitaxel).
  • In addition, retinol-related genes such as CRABP2 and retinol-binding protein 1 were overexpressed in WT, and CRABP2 was more highly expressed in the poor outcome patients, which suggests that retinoid acid may be a potential drug.
  • In summary, our findings suggest that the integration of gene expression data and clinical parameters could aid in detecting aggressive tumors among favorable histology WT and lead to the discovery of new drugs for WT.
  • [MeSH-major] Kidney Neoplasms / genetics. Kidney Neoplasms / pathology. Wilms Tumor / genetics. Wilms Tumor / pathology
  • [MeSH-minor] Antigens, Neoplasm. Carcinoma, Renal Cell / genetics. Carcinoma, Renal Cell / metabolism. Carcinoma, Renal Cell / pathology. Carcinoma, Renal Cell / surgery. Child, Preschool. Cluster Analysis. DNA Topoisomerases, Type II / biosynthesis. DNA Topoisomerases, Type II / genetics. DNA-Binding Proteins. Gene Expression Profiling. Gene Expression Regulation, Neoplastic. Humans. Infant. Insulin-Like Growth Factor II / biosynthesis. Insulin-Like Growth Factor II / genetics. Neoplasm Staging. Oligonucleotide Array Sequence Analysis. Reverse Transcriptase Polymerase Chain Reaction. Treatment Outcome. WT1 Proteins / biosynthesis. WT1 Proteins / genetics

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • MedlinePlus Health Information. consumer health - Wilms Tumor.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12438255.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / DNA-Binding Proteins; 0 / WT1 Proteins; 67763-97-7 / Insulin-Like Growth Factor II; EC 5.99.1.3 / DNA Topoisomerases, Type II; EC 5.99.1.3 / DNA topoisomerase II alpha
  •  go-up   go-down


8. Balaguer Guill J, Fernández Navarro JM, Cañete Nieto A, Muro Velilla MD, Hernández Martí M, Castel Sánchez V: [Renal tumors in infants aged less than 1 year]. An Pediatr (Barc); 2006 May;64(5):433-8
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Renal tumors in infants aged less than 1 year].
  • [Transliterated title] Tumores renales en niños menores de un año.
  • OBJECTIVE: To determine the frequency and distribution of primary renal tumors diagnosed in a pediatric oncology unit in children younger than 1 year and identify their clinical and histopathological characteristics, the treatment used, and outcomes.
  • MATERIAL AND METHODS: We retrospectively reviewed the medical records of infants with primary tumors of the kidney diagnosed between January 1972 and February 2003.
  • RESULTS: A total of 137 tumors were diagnosed in our unit during the period studied.
  • Among the 15 WT, 9 were stage I, 1 was stage II, one was stage III, 2 were stage IV, and 1 was stage V.
  • Overall survival at 5 years was 0.67 (SE 0.12) for WT and 0.89 (SE 0.1) for MN, respectively, with a mean follow-up of 290 months.
  • The first-line therapy in these patients is surgery since this type of tumor shows little chemosensitivity and chemotherapy is poorly tolerated in infants.
  • [MeSH-major] Kidney Neoplasms

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16756884.001).
  • [ISSN] 1695-4033
  • [Journal-full-title] Anales de pediatría (Barcelona, Spain : 2003)
  • [ISO-abbreviation] An Pediatr (Barc)
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


9. Li Q, Feng FY, Chen Q, Jiao SC, Li F, Wang HQ, Huang WX, Ling CQ, Li MZ, Ren J, Zhang Y, Qin FZ, Zhou MZ, Zhu RZ: [Multicenter phase II clinical trial of uroacitides injection in the treatment for advanced malignant tumors]. Zhonghua Zhong Liu Za Zhi; 2008 Jul;30(7):534-7
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Multicenter phase II clinical trial of uroacitides injection in the treatment for advanced malignant tumors].
  • OBJECTIVE: To investigate the efficacy, safety and the life quality improvement of uroacitides injection in the treatment for patients with advanced malignant tumors.
  • METHODS: A total of 160 patients with advanced stage cancers were enrolled into this multicenter, open and non-randomized phase II clinical trial, including cancers of the lung (33 cases), liver (45 cases), breast (17 cases), esophagus (11 cases), stomach (18 cases), colon (19 cases), pancreas (3 cases) and kidney (4 cases), and glioma (10 cases).
  • Major adverse effects were grade I - II and reversible nausea/vomiting (21.9%) and pain (6.3%).
  • [MeSH-major] Liver Neoplasms / drug therapy. Lung Neoplasms / drug therapy. Methyltransferases / therapeutic use. Peptides / therapeutic use. Phenylacetates / therapeutic use
  • [MeSH-minor] Breast Neoplasms / blood. Breast Neoplasms / drug therapy. Breast Neoplasms / pathology. CA-19-9 Antigen / blood. Carcinoembryonic Antigen / blood. Carcinoma, Non-Small-Cell Lung / blood. Carcinoma, Non-Small-Cell Lung / drug therapy. Carcinoma, Non-Small-Cell Lung / pathology. Catheterization, Central Venous. Colorectal Neoplasms / blood. Colorectal Neoplasms / drug therapy. Colorectal Neoplasms / pathology. Humans. Nausea / chemically induced. Neoplasm Staging. Quality of Life. Remission Induction. Salvage Therapy. Treatment Outcome. Vomiting / chemically induced. alpha-Fetoproteins / metabolism

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19062723.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] Clinical Trial, Phase II; English Abstract; Journal Article; Multicenter Study
  • [Publication-country] China
  • [Chemical-registry-number] 0 / CA-19-9 Antigen; 0 / Carcinoembryonic Antigen; 0 / Peptides; 0 / Phenylacetates; 0 / alpha-Fetoproteins; 0 / cell differentiation agent II; EC 2.1.1.- / Methyltransferases
  •  go-up   go-down


10. Vujanić GM, Sandstedt B, Harms D, Kelsey A, Leuschner I, de Kraker J, SIOP Nephroblastoma Scientific Committee: Revised International Society of Paediatric Oncology (SIOP) working classification of renal tumors of childhood. Med Pediatr Oncol; 2002 Feb;38(2):79-82
MedlinePlus Health Information. consumer health - Wilms Tumor.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Revised International Society of Paediatric Oncology (SIOP) working classification of renal tumors of childhood.
  • The previous International Society of Paediatric Oncology (SIOP) trials and studies recognized three prognostic groups of renal tumors of childhood: low risk, intermediate risk, and high risk tumors, which were further defined in the SIOP (Stockholm) Working Classification of Renal Tumors of Childhood (1994).
  • The results of the latest SIOP Trials and Studies showed that certain histological features which remain after preoperative chemotherapy, such as blastema, are of prognostic significance while others are not.
  • Therefore, in the next SIOP Trials and Study a revised classification of renal tumors will be followed.
  • It still recognizes the three tumor risk groups with different types in each of them, but for treatment purposes, only three major types of nephroblastoma need to be recognized: completely necrotic (low risk tumor), blastemal (high risk tumor), and others (intermediate risk tumors).
  • Patients will be treated according to tumor histology and stage.
  • Trials which include preoperative chemotherapy have shown that the presence of necrotic tumor or chemotherapy induced changes in the renal sinus or perirenal fat can be ignored for distinguishing between stage I and II, but if present at resection margins or lymph nodes, it should be regarded as stage III.
  • Prognostic significance of all histological component of Wilms tumors will be studied prospectively in the new trial.
  • [MeSH-major] Kidney Neoplasms / pathology. Wilms Tumor / pathology

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2002 Wiley-Liss, Inc.
  • [CommentIn] Med Pediatr Oncol. 2003 Jul;41(1):102 [12764768.001]
  • [CommentIn] Med Pediatr Oncol. 2002 Feb;38(2):77-8 [11813169.001]
  • (PMID = 11813170.001).
  • [ISSN] 0098-1532
  • [Journal-full-title] Medical and pediatric oncology
  • [ISO-abbreviation] Med. Pediatr. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Genetic Markers
  •  go-up   go-down


11. Goel MC, Mahendra V, Roberts JG: Percutaneous management of renal pelvic urothelial tumors: long-term followup. J Urol; 2003 Mar;169(3):925-9; discussion 929-30
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Percutaneous management of renal pelvic urothelial tumors: long-term followup.
  • Patients with low stage pT0-1 disease were treated primarily with percutaneous surgery.
  • All pelvicaliceal tumors were taken for biopsy and treated with percutaneous resection.
  • Patients with multi-segmental pelvicaliceal system involvement, stage greater than pT1, high grade histology or additional ureteral tumors were considered for nephroureterectomy.
  • Topical chemotherapy (mitomycin C or epirubicin) was administered via nephrostomy tube or intravesical instillation after Double-J stent (Medical Engineering Corp., New York, New York) insertion.
  • RESULTS: Of the 24 cases 2 had squamous cell carcinoma, 5 had grade III transitional cell carcinoma, 15 had grade I to II transitional cell carcinoma and 2 had no tumor.
  • Early recurrences were detected by excretory urography (IVP) in 3 cases, small pelvic recurrences by IVP in 2, fiberoptic ureterorenoscopy in 2 and bladder tumors by flexible cystoscopy in 3 after 1 year.
  • Three synchronous, grade I bladder tumors were managed conventionally.
  • All patients with high grade disease died of malignancy except one (with no further treatment) and 6 of the 15 patients with low grade noninvasive transitional cell carcinoma underwent nephroureterectomy during followup either due to progression of disease, concomitant tumor or complications.
  • High grade tumors or tumors greater than T1 were treated with nephroureterectomy early during management.
  • CONCLUSIONS: Percutaneous resection of transitional cell tumor should be considered primarily in patients with early stage disease excluding tumors crossing caliceal infundibula, ureteropelvic junction tumor, tumor extending over multiple calices and synchronous ureteral tumors.
  • The long-term outcome of low grade tumors is good and they should be managed by either form of minimally invasive surgery.
  • Nephron sparing is possible in a large percentage of low grade disease but high grade tumors should be treated with nephroureterectomy.
  • [MeSH-major] Carcinoma, Transitional Cell / therapy. Kidney Neoplasms / therapy
  • [MeSH-minor] Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / therapy. Endoscopy. Female. Follow-Up Studies. Humans. Kidney Pelvis. Male. Middle Aged. Neoplasm Recurrence, Local. Nephrectomy. Ureter / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Urol. 2003 Mar;169(3):936-7 [12576816.001]
  • (PMID = 12576814.001).
  • [ISSN] 0022-5347
  • [Journal-full-title] The Journal of urology
  • [ISO-abbreviation] J. Urol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


12. Gupta V, Weigand T, Rangineni R: Phase I-II dose escalation study of celecoxib (C) in combination with paclitaxel (T) and carboplatinum (CP) in non small cell lung cancer (NSCLC). J Clin Oncol; 2004 Jul 15;22(14_suppl):7310

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I-II dose escalation study of celecoxib (C) in combination with paclitaxel (T) and carboplatinum (CP) in non small cell lung cancer (NSCLC).
  • : 7310 Background: Preclinical data suggests COX-2 inhibitors prevent development of cancer,shrink established tumors,and inhibit angiogenesis in dose dependent manner with "optimal"blood levels of 1.8-5ug/ml of celecoxib(C).
  • METHODS: 34 patients with inoperable stage I-III and IV, with evaluable disease and PS 1,2 received C and prophylaxis with H2 blockers or proton pump inhibitors for 7d prior to CP AUC- 6 q4wks and T60mg/m2 weekly for at least 4 mo.Dose escalation of C was after 4 patients at each dose level.
  • GI and other side effects,heme,liver, kidney function were monitored weekly.
  • 2 patients had received prior non-taxane therapy.
  • Patients with StageI-III disease after 4mo induction chemotherapy received consolidation radiotherapy with or without chemotherapy.
  • There were 22 patients evaluable for response with 3CR,6PR,10SD, 3 progressive after 4mo of therapy.
  • One stage IV patient with brain mets at 800mg of C died postop with GI bleed from incidental carcinoid of small bowel and one at 1600mg of C(blood level 1200ng/ml) after anticoagulation for DVT(INR 2.4), and one at 800mg mg of C from grade 4 neutropenia and pneumonia.
  • 3. "Optimal" blood levels of celecoxib may not be easily achieved at 800mg/d of celecoxib and may require therapeutic monitoring to properly asses impact in clinical trials.
  • 4. The therapeutic role of celecoxib in combination with chemotherapy or by itself requires ongoing investigation.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28015039.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


13. Tröbs RB, Hänsel M, Friedrich T, Bennek J: A 23-year experience with malignant renal tumors in infancy and childhood. Eur J Pediatr Surg; 2001 Apr;11(2):92-8
MedlinePlus Health Information. consumer health - Wilms Tumor.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A 23-year experience with malignant renal tumors in infancy and childhood.
  • A retrospective analysis of 77 children treated between 1974 and 1996 was undertaken to evaluate morbidity and the evolution of therapy.
  • Among patients with Wilms' tumors (WT), nephroblastoma (NB) of intermediate risk predominated (73%; 46 of 63 pats.).
  • Low-risk tumors occurred in 5 of 63 children (8%; mesoblastic nephroma 3, cystic partially diff.
  • Comparing relapse-free survival of stages I, II and III, respectively, there was a reduced survival rate for stage III (p=0.019).
  • According to the SIOP/GPOH protocol in 1989, the regimen was switched from primary surgery to preoperative chemotherapy without biopsy in 1989 (11 pats.).
  • During preoperative chemotherapy a venous occlusive disease of the liver occurred in 2 patients.
  • Preoperative chemotherapy led to an impressive tumor shrinkage in the majority of patients.
  • In our experience, reduction of tumor volume due to preoperative chemotherapy facilitates tumor removal by surgery and may prevent tumor spillage and the deleterious effects of radiation in young children.
  • Surgery without delay is necessary if the diagnosis is unclear or the tumor fails to respond to preoperative chemotherapy.
  • [MeSH-major] Kidney Neoplasms / surgery. Wilms Tumor / surgery
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Chemotherapy, Adjuvant. Child. Child, Preschool. Disease-Free Survival. Female. Humans. Infant. Male. Neoplasm Recurrence, Local / epidemiology. Neoplasm Staging. Prognosis. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11371043.001).
  • [ISSN] 0939-7248
  • [Journal-full-title] European journal of pediatric surgery : official journal of Austrian Association of Pediatric Surgery ... [et al] = Zeitschrift für Kinderchirurgie
  • [ISO-abbreviation] Eur J Pediatr Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


14. Koga Y, Matsuzaki A, Suminoe A, Hatano M, Saito Y, Kinoshita Y, Tajiri T, Taguchi T, Kohashi K, Oda Y, Tsuneyoshi M, Hara T: Long-term survival after autologous peripheral blood stem cell transplantation in two patients with malignant rhabdoid tumor of the kidney. Pediatr Blood Cancer; 2009 Jul;52(7):888-90
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term survival after autologous peripheral blood stem cell transplantation in two patients with malignant rhabdoid tumor of the kidney.
  • A 5-month-old male with stage II malignant rhabdoid tumor of the kidney (MRTK) and a 24-month-old male with stage III MRTK were treated with surgical resection of tumors and chemotherapy of alternating ICE (ifosfamide, carboplatin, and etoposide) and VDC (vincristine, doxorubicin, and cyclophosphamide), followed by high-dose chemotherapy using etoposide, carboplatin, and melphalan with autologous hematopoietic stem cell transplantation (SCT).
  • Two patients have been alive without any evidence of disease for 30 and 37 months after diagnosis, respectively, and require no medication.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hematopoietic Stem Cell Transplantation. Kidney Neoplasms / mortality. Kidney Neoplasms / therapy. Rhabdoid Tumor / mortality. Rhabdoid Tumor / therapy
  • [MeSH-minor] Carboplatin / administration & dosage. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Etoposide / administration & dosage. Humans. Ifosfamide / administration & dosage. Infant. Male. Melphalan / administration & dosage. Prognosis. Survival Rate. Tomography, X-Ray Computed. Transplantation, Autologous. Treatment Outcome. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Rhabdoid tumor.
  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. MELPHALAN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2009 Wiley-Liss, Inc.
  • (PMID = 19260106.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; BG3F62OND5 / Carboplatin; Q41OR9510P / Melphalan; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


15. El Kababri M, Khattab M, El Khorassani M, Hessissen L, Kili A, Nachef MN, Cherradi N, Malihy A, Alhamany Z, Msefer-Alaoui F: [Clear cell sarcoma of the kidney. A study of 13 cases]. Arch Pediatr; 2004 Jul;11(7):794-9
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clear cell sarcoma of the kidney. A study of 13 cases].
  • [Transliterated title] Sarcome rénal à cellules claires. A propos d'une série de 13 cas.
  • Clear cell sarcoma of the kidney (CCSK) also called a "bone-metastasizing renal tumor of childhood" is the second common pediatric renal neoplasm.
  • PATIENTS AND METHODS: We have reviewed records of 13 cases of CCSK among 277 renal tumors (5%) diagnosed at the children's hospital of Rabat between 1990 and 2002.
  • Preoperative chemotherapy was given according to the SIOP9, SIOP93-01 and GFAOP 98 protocols.
  • The distribution local stage was I: three cases; II: three cases; III: six cases; IV: one case.
  • Postoperative chemotherapy and radiotherapy (21 600-30 600 cGy) was done in 10 cases.
  • Its aggressiveness and its ability to give bone metastases need to recognize early this diagnosis for an adapted treatment.
  • [MeSH-major] Kidney Neoplasms / pathology. Kidney Neoplasms / surgery. Nephrectomy. Sarcoma, Clear Cell / pathology. Sarcoma, Clear Cell / surgery
  • [MeSH-minor] Age of Onset. Child. Child, Preschool. Combined Modality Therapy. Female. Humans. Infant. Male. Neoadjuvant Therapy. Neoplasm Staging. Prognosis. Retrospective Studies. Sex Factors. Survival Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15234374.001).
  • [ISSN] 0929-693X
  • [Journal-full-title] Archives de pédiatrie : organe officiel de la Sociéte française de pédiatrie
  • [ISO-abbreviation] Arch Pediatr
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] France
  •  go-up   go-down


16. Sawicz-Birkowska K, Czernik J, Bagłaj M, Czauderna P, Kantorowicz-Szymik S, Poznański WA, Mańkowski P, Madziara W, Prokurat A, Osemlak J: [Renal neoplasms in children]. Przegl Lek; 2004;61 Suppl 2:20-3
MedlinePlus Health Information. consumer health - Wilms Tumor.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Nephroblastoma is the most common kidney tumor in Polish children.
  • OBJECTIVE: to present clinical material and outcome of 533 children with renal tumors.
  • MATERIAL: 500 pts with nephroblastoma and 33 of non-Wilms: CMN, RCC,CSSK, RTK and others tumors were registered, mean age 4.5 years between 1993 till 2002.
  • Stage: CS I--148, CS II--191, CS III--114, CS IV--51, CS V--29 pts.
  • All pts with nephroblastoma were treated according to the first national PPGGL 01-92 protocol with pre-operative chemotherapy (ACT, VCR) for CS I-III and ACT, VCR, DOX in pts of stage IV, over the age of 6 months.
  • Pre-operative chemotherapy was done to 93.8% pts.
  • RESULTS: Radical nephrectomy post pre op chemotherapy was performed in 451 (98%) pts over 6 months and in 44 (8.2%) infants less than 6 months with nephroblastoma.
  • Partial nephrectomy for unilateral tumor post preoperative chemotherapy was made in 6 (1.2%).
  • In 26/29 (89.65%) of CS V nephroblastoma kidney sparing surgery was possible, and in 12 uni-lateral nephrectomy was performed.
  • RESULTS: 5-years overall survival of CS I pts (favorable and standard histology) is 93.48%, CS II--96.8%, CS III--84.4%, CS IV--67%, CS V--58%.
  • The results of treatment of 33 pts with non-Wilms renal tumors have improved lately.
  • CONCLUSIONS: The use of systemic neoadjuvant chemotherapy in all pts over 6 months according to the recommendation of SIOP Nephroblastoma protocol (01-92) produced tumor shrinkage, facilitated complete surgical nephrectomy, and was very advantageous in the treatment of renal tumors in children.
  • The results of treatment of non-Wilms tumor have also improved thanks to introduction of new and more aggressive regimens of chemotherapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Kidney Neoplasms / drug therapy. Kidney Neoplasms / surgery. Nephrectomy. Wilms Tumor / drug therapy. Wilms Tumor / surgery
  • [MeSH-minor] Adolescent. Chemotherapy, Adjuvant. Child. Child, Preschool. Disease-Free Survival. Female. Humans. Infant. Infant, Newborn. Male. Neoadjuvant Therapy. Neoplasm Staging. Poland. Prognosis. Remission Induction. Retrospective Studies. Risk Factors. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15686041.001).
  • [ISSN] 0033-2240
  • [Journal-full-title] Przegla̧d lekarski
  • [ISO-abbreviation] Prz. Lek.
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


17. Rini BI, Wilding G, Hudes G, Stadler WM, Kim S, Tarazi J, Rosbrook B, Trask PC, Wood L, Dutcher JP: Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma. J Clin Oncol; 2009 Sep 20;27(27):4462-8
Hazardous Substances Data Bank. NICOTINAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma.
  • PURPOSE: To investigate the efficacy and safety of axitinib, an oral, potent, and selective inhibitor of vascular endothelial growth factor (VEGF) receptors 1, 2, and 3 in patients with metastatic renal cell carcinoma (mRCC) refractory to prior therapies that included, but were not limited to, sorafenib.
  • PATIENTS AND METHODS: In this multicenter, open-label, phase II study, patients with sorafenib-refractory mRCC received a starting dose of axitinib 5 mg orally twice daily.
  • A one-arm, single-stage design was used to estimate the primary end point of objective response rate (ORR), defined by RECIST (Response Evaluation Criteria in Solid Tumors).
  • RESULTS: Of 62 patients recruited, 100% had received prior sorafenib, and 74.2% had received two or more prior systemic treatments.
  • Median PFS and OS times were 7.4 months (95% CI, 6.7 to 11.0 months) and 13.6 months (95% CI, 8.4 to 18.8 months), respectively.
  • CONCLUSION: Axitinib has antitumor activity in patients with mRCC refractory to prior VEGF-targeted therapy, including sorafenib.
  • A randomized, phase III trial to compare axitinib with sorafenib in patients who have mRCC refractory to one prior first-line therapy regimen is underway.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carcinoma, Renal Cell / drug therapy. Imidazoles / therapeutic use. Indazoles / therapeutic use. Kidney Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Benzenesulfonates / therapeutic use. Female. Humans. Male. Middle Aged. Niacinamide / analogs & derivatives. Phenylurea Compounds. Pyridines / therapeutic use

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19652060.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzenesulfonates; 0 / Imidazoles; 0 / Indazoles; 0 / Phenylurea Compounds; 0 / Pyridines; 25X51I8RD4 / Niacinamide; 9ZOQ3TZI87 / sorafenib; C9LVQ0YUXG / axitinib
  •  go-up   go-down


18. Reinhard H, Semler O, Bürger D, Bode U, Flentje M, Göbel U, Gutjahr P, Leuschner I, Maass E, Niggli F, Scheel-Walter HG, Stöckle M, Thüroff JW, Tröger J, Weirich A, von Schweinitz D, Zoubek A, Graf N: Results of the SIOP 93-01/GPOH trial and study for the treatment of patients with unilateral nonmetastatic Wilms Tumor. Klin Padiatr; 2004 May-Jun;216(3):132-40
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Results of the SIOP 93-01/GPOH trial and study for the treatment of patients with unilateral nonmetastatic Wilms Tumor.
  • BACKGROUND: The treatment of Wilms Tumor is integrated into clinical trials since the 1970's.
  • In contrast to the National Wilms Tumor Study Group (NWTSG) the SIOP trials and studies largely focus on the issue of preoperative therapy to facilitate surgery of a shrunken tumor and to treat metastasis as early as possible.
  • 847 of them had a histological proven Wilms Tumor, of whom 637 were unilateral localized, and 173 tumors had an other histology [40 congenital mesoblastic nephroma (CMN), 51 clear cell sarcoma (CCSK), 24 rhabdoid tumor (RTK) and 58 other tumors].
  • Preoperative chemotherapy in benign tumors was given to 1.3 % of the patients.
  • The main objective of the trial was the randomized question, if the postoperative two drug chemotherapy for stage I in intermediate risk or anaplasia can be reduced from conventional 3 courses to an experimental 1 course without loss of efficacy.
  • RESULTS: 519 patients with unilateral nonmetastatic Wilms did receive preoperative chemotherapy.
  • The histology in this group of patients was of intermediate risk in 469 (90 %) patients, 14 (3 %) tumors were low risk and 36 (7 %) high risk.
  • The stage distribution of the tumors was stage I in 315 (61 %), stage II N- in 126 (24 %), stage II N+ in 25 (5 %) and stage III in 36 (7 %) patients.
  • In 17 (3 %) patients the tumor stage remained unclear.
  • Tumor volume was measured in 487 patients before and in 402 after preoperative chemotherapy.
  • Randomisation was done in 43.7 % for stage I patients and there was no difference in EFS for both treatment arms (90 versus 91 %).
  • The EFS is identical for patients with stage I and II N- (0.92), as well as for stage II N+ and III (0.82).
  • The tumor volume after chemotherapy is a prognostic factor for intermediate risk tumors with the exception of epithelial and stromal predominant tumors.
  • These two subtypes often present as large tumors, they do not shrink during preoperative chemotherapy but they still have an excellent prognosis.
  • On the other hand the prognosis of patients with blastemal predominant subtype after preoperative chemotherapy is worse than in any other patient group of intermediate risk tumors.
  • There are less blastemal predominant tumors compared to primary surgery, but they are chemotherapeutic resistant selected by the preoperative chemotherapy.
  • The post-operative chemotherapy in stage I can be reduced to 4 weeks without worsening treatment outcome.
  • The reduction of the tumor volume could be identified as a helpful marker for stratification of post-operative treatment.
  • Post-chemotherapy blastemal predominant subtype of Wilms tumor has to be classified as high risk tumor.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Kidney Neoplasms / drug therapy. Neoadjuvant Therapy. Wilms Tumor / drug therapy
  • [MeSH-minor] Adolescent. Chemotherapy, Adjuvant. Child. Child, Preschool. Combined Modality Therapy. Disease-Free Survival. Female. Follow-Up Studies. Humans. Infant. Male. Neoplasm Staging. Nephrectomy. Nephroma, Mesoblastic / drug therapy. Nephroma, Mesoblastic / mortality. Nephroma, Mesoblastic / pathology. Nephroma, Mesoblastic / surgery. Prognosis. Rhabdoid Tumor / drug therapy. Rhabdoid Tumor / mortality. Rhabdoid Tumor / pathology. Rhabdoid Tumor / surgery. Sarcoma, Clear Cell / drug therapy. Sarcoma, Clear Cell / mortality. Sarcoma, Clear Cell / pathology. Sarcoma, Clear Cell / surgery

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • MedlinePlus Health Information. consumer health - Wilms Tumor.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15175957.001).
  • [ISSN] 0300-8630
  • [Journal-full-title] Klinische Pädiatrie
  • [ISO-abbreviation] Klin Padiatr
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  •  go-up   go-down


19. Tournade MF, Com-Nougué C, de Kraker J, Ludwig R, Rey A, Burgers JM, Sandstedt B, Godzinski J, Carli M, Potter R, Zucker JM, International Society of Pediatric Oncology Nephroblastoma Trial and Study Committee: Optimal duration of preoperative therapy in unilateral and nonmetastatic Wilms' tumor in children older than 6 months: results of the Ninth International Society of Pediatric Oncology Wilms' Tumor Trial and Study. J Clin Oncol; 2001 Jan 15;19(2):488-500
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Optimal duration of preoperative therapy in unilateral and nonmetastatic Wilms' tumor in children older than 6 months: results of the Ninth International Society of Pediatric Oncology Wilms' Tumor Trial and Study.
  • PURPOSE: To determine the optimal duration of preoperative chemotherapy to further increase the proportion of stage I tumors by comparison of two regimens in the treatment of patients older than 6 months who have unilateral Wilms' tumor.
  • PATIENTS AND METHODS: Eligible patients (n = 382) initially received four weekly doses of vincristine (VCR) and two courses of actinomycin D (AMD) and were randomized either to be operated on (4-week group [n = 193]) or to receive 4 more weeks of the same chemotherapy regimen (8-week group [n = 189]).
  • The assessment criterion was the observed percentage of stage I tumors.
  • After surgery, patients were assigned according to tumor stage and histology to four different treatment groups: stage I and favorable histology (n = 5) were to have no further treatment (NFT); stage I and standard histology or anaplasia (n = 244), VCR and AMD for 17 weeks (AV); stages II and III and favorable or standard histology, VCR, AMD, and an anthracycline for 27 weeks (AVE) with no abdominal radiotherapy for stage II N0 disease (n = 75) or with a 15-Gy dose of abdominal irradiation (RTH) in case of stages IIN1 and III (n = 56).
  • Anaplastic tumors staged higher than I or clear-cell sarcoma of the kidney (14), AMD, VCR, an anthracycline, and ifosfamide for 36 weeks (DEVI).
  • RESULTS: No advantage was found in favor of prolonged preoperative treatment.
  • The percentages obtained for the 4-week and the 8-week groups, respectively, were as follows: stage I, 64% versus 62%; intraoperative tumor rupture rate, 1% versus 3%; 2-year EFS, 84% versus 83%; and 5-year OS, 92% versus 87%.
  • Two-year EFS and 5-year OS rates, respectively, of the different treatment groups were as follows: NFT, 100% for both EFS and OS; AV, 88% and 93%; AVE, 84% and 88%; AVE RTH, 71% and 85%; and DEVI, 71% and 71%.
  • The rate of abdominal recurrences in stage II N0 nonirradiated patients was 6.6%.
  • CONCLUSION: The 4-week schedule pre-nephrectomy chemotherapy regimen should be considered the standard treatment.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Kidney Neoplasms / drug therapy. Wilms Tumor / drug therapy
  • [MeSH-minor] Adolescent. Antibiotics, Antineoplastic / administration & dosage. Chemotherapy, Adjuvant. Child. Child, Preschool. Dactinomycin / administration & dosage. Drug Administration Schedule. Humans. Infant. Neoplasm Staging. Nephrectomy. Survival Analysis. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Wilms' tumor.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • MedlinePlus Health Information. consumer health - Wilms Tumor.
  • Hazardous Substances Data Bank. DACTINOMYCIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11208843.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 1CC1JFE158 / Dactinomycin; 5J49Q6B70F / Vincristine
  •  go-up   go-down


20. Kaur N, Gupta A, Attam A, Shrivastava UK, Wadhwa N: Adult Wilms' tumor: management considerations. Int Urol Nephrol; 2005;37(1):17-20
MedlinePlus Health Information. consumer health - Wilms Tumor.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Adult Wilms' tumor are rare tumors.
  • Recommended treatment guidelines are similar to those followed for Wilms' tumor of childhood.
  • Presented herein is a case of an adult Wilms' tumor stage II favorable histology which failed to respond to the first line combination chemotherapy schedule of cyclophosphomide, vincristine, and actinomycin D.
  • In view of similar such reports in the literature a more aggressive chemotherapy schedule of cisplatin and etoposide based combination may be recommended as the first line of treatment for early stage adult Wilms' tumor.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Kidney Neoplasms / surgery. Wilms Tumor / surgery
  • [MeSH-minor] Adult. Combined Modality Therapy. Humans. Male. Neoplasm Invasiveness. Radiography

  • Genetic Alliance. consumer health - Wilms' tumor.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1988 Sep 1;62(5):1017-21 [2842024.001]
  • [Cites] J Clin Oncol. 1994 May;12(5):931-6 [8164044.001]
  • [Cites] Cancer. 1990 Feb 15;65(4):890-2 [1688729.001]
  • [Cites] J Pediatr Surg. 1991 May;26(5):610-2 [1648128.001]
  • [Cites] Cancer. 1980 Apr 1;45(7):1713-9 [6245783.001]
  • [Cites] Cancer. 1997 Nov 15;80(10 ):1961-5 [9366299.001]
  • [Cites] J Surg Oncol. 1988 Dec;39(4):283-6 [2848158.001]
  • [Cites] Urology. 1995 Jun;45(6):1055-8 [7771010.001]
  • [Cites] J Urol. 1984 Jul;132(1):108-10 [6328049.001]
  • [Cites] Am J Roentgenol Radium Ther Nucl Med. 1969 Jan;105(1):95-104 [4304468.001]
  • (PMID = 16132751.001).
  • [ISSN] 0301-1623
  • [Journal-full-title] International urology and nephrology
  • [ISO-abbreviation] Int Urol Nephrol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


21. Tang JY, Pan C, Xu M, Xue HL, Chen J, Zhao HL, Gu LL, Wang YP: [Results of Wilms' tumor trial (WT-99) in Shanghai children's medical center]. Zhonghua Er Ke Za Zhi; 2003 Feb;41(2):131-4
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: Wilms' Tumor Trial (WT-99) of Shanghai Children's Medical Center was designed and conducted by applying therapeutic regimens stratified by stage and histology in accordance with National Wilms' Tumor Study (NWTS) criteria of U.S.A.
  • The main aim of WT-99 was to reduce treatment of low-stage, favorable-histology (FH) tumors without impairing survival and to improve prognosis of stage III and IV (FH) and unfavorable-histology (UFH) tremors with more intensive chemotherapy.
  • METHODS: Diagnosis and treatment was decided by the multi-disciplinary team including oncologists, surgeons, pathologists, radiologists and diagnostic radiologists.
  • The regimen for patients at favorable-histology (FH) stage I and II and anaplastic stage I was vincristine (Vcr) and dactinomycin (Act-D) only, while for those at focal anaplastic stage II to IV and FH stage III and IV the regimen was Vcr, Act-D and adriamycin (Adr).
  • Patients at diffuse anaplastic stage II to IV and clear cell stage I to IV received four-drug regimen including Vcr, etoposide (VP16), Adr and cytoxan (CTX).
  • For those at rhabdoid stage I to IV the regimen was carboplatin, VP-16 and CTX.
  • Un-resectable patients received 2 courses of Ifosfamide, Vcr and VP-16 as pre-surgery therapy.
  • No radiation therapy was used for patients at stage I and FH stage II.
  • Pathologic analysis showed fourteen cases were at their FH, three at unfavorable-histology (UFH), two at clear cell and one at rhabdoid stage.
  • Five patients were at stage I, five at stage II, six at stage III, three at stage IV and one at stage V.
  • One relapsed after 24 months of CCR and reached the second CR after intensive chemotherapy.
  • No therapy-related death happened.
  • [MeSH-major] Kidney Neoplasms / therapy. Wilms Tumor / therapy
  • [MeSH-minor] Academic Medical Centers. Bone Transplantation. Child. Child, Preschool. China. Combined Modality Therapy. Female. Humans. Infant. Male. Neoplasm Staging. Transplantation, Autologous. Treatment Outcome


22. Calvo Rodríguez M, Fírvida Pérez JL, Vega Vázquez F, Salgado Fernández M, García Mata J, Rubén Rodríguez M, Barreiro Mouro A: [Wilms tumor in the adult]. Arch Esp Urol; 2001 May;54(4):370-4
MedlinePlus Health Information. consumer health - Wilms Tumor.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Tumor de Wilms del adulto.
  • Physical examination and patient assessment by ultrasound and CT showed a solid tumor in the right kidney.
  • Pathological analysis demonstrated a biphasic nephroblastoma (Wilms' tumor) with infiltration of renal hilar fat (stage II).
  • After surgery, adjuvant chemotherapy with vincristine-actinomycin D was administered for 60 weeks.
  • CONCLUSIONS: Although rare in adults, Wilms' tumor should be included in the differential diagnosis of all renal tumors.
  • Treatment is usually by surgery and chemotherapy with or without radiotherapy, depending on tumor stage.
  • [MeSH-major] Kidney Neoplasms / pathology. Wilms Tumor / pathology

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11455774.001).
  • [ISSN] 0004-0614
  • [Journal-full-title] Archivos españoles de urología
  • [ISO-abbreviation] Arch. Esp. Urol.
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


23. Sato H, Hori K, Sugiyama K, Tanda S, Sato Y: [Tumor microcirculation and selective enhancement of drug delivery--clinical applications based on pathophysiological experiments]. Gan To Kagaku Ryoho; 2000 Jul;27(8):1191-200
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Tumor microcirculation and selective enhancement of drug delivery--clinical applications based on pathophysiological experiments].
  • Tumor tissue is composed of cancer cells (parenchyma) and tumor vessels (interstitium).
  • Many investigators have pointed out that blood flow in tumors has a very inhomogenous distribution, and that this inhomogeneity in blood flow increases as tumors grew.
  • This would be a certain cause of insufficient drug delivery to tumor tissues.
  • Among the experimental evidence using Yoshida Sarcoma and Ascites Hepatomas, functional differences in microcirculation between tumor and normal tissues were found by Suzuki et al. (1977).
  • Under hypertensive state induced by the continuous infusion of angiotensin II, tumor blood flow increased remarkably, while there was no change or decrease in blood flow in normal tissues such as the brain, bone marrow, liver and kidney.
  • Moreover, the increase in blood flow in tumors was selective, as the mean blood pressure remained at the level of 150 mmHg.
  • Increases were confirmed not only in many growing sites such as in the liver, muscle, subcutis, and even microfoci, but also in various kinds of xenografted human tumors and autochthonous tumors.
  • Augmentation of the anti-tumor effects of angiotensin II-induced hypertension chemotherapy (IHC) for advanced gastric carcinoma was revealed in two randomized controlled trials (RCT-1 & 2) of collaborative study groups in Japan.
  • In the results of phase II studies from 1978 to 1994 (OPN-1) and 1995 to 1999 (OPN-2) for advanced gastric carcinoma (GC), the response rates were 37.9% and 35.7%.
  • Down staging in which the conclusive stage score was lower than the score of the clinical stage, was observed in 8 out of 94 cases (19%) with primary lesions in total and in 30 patients (63%) receiving reduction surgery after IHC, since 1978.
  • It is very important for exact evaluation after chemotherapy to understand or estimate the pathohistological changes in the tumor and its degenerated or repaired tissues, which present various clinical images.
  • IHC with smaller DI could lead to a reduction in the accumulation of toxicities of anti-cancer drugs in the host.
  • In conclusion, IHC might be applied to all kinds of tumors to enhance the chemotherapeutic effects through selective increase of drug delivery to tumors.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Drug Delivery Systems / methods. Sarcoma, Yoshida / blood supply. Sarcoma, Yoshida / drug therapy. Stomach Neoplasms / drug therapy
  • [MeSH-minor] Animals. Blood Pressure / drug effects. Doxorubicin / administration & dosage. Drug Administration Schedule. Fluorouracil / administration & dosage. Humans. Microcirculation. Mitomycin / administration & dosage. Rats

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10945016.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] JAPAN
  • [Chemical-registry-number] 50SG953SK6 / Mitomycin; 80168379AG / Doxorubicin; U3P01618RT / Fluorouracil; FAM protocol
  • [Number-of-references] 77
  •  go-up   go-down


24. Okazaki T, Kohno S, Mimaya J, Hasegawa S, Urushihara N, Yoshida A, Kawano S, Kusafuka J, Horikoshi Y, Takashima Y, Aoki K, Hamazaki M: Neuroblastoma detected by mass screening: the Tumor Board's role in its treatment. Pediatr Surg Int; 2004 Jan;20(1):27-32
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neuroblastoma detected by mass screening: the Tumor Board's role in its treatment.
  • Criteria for the observation program were stage-I, stage-II, or stage-IVs tumors, urinary vanillylmandelic acid (VMA) and homovanillic acid (HVA) levels <40 microg/mg creatinine, tumor <5 cm in diameter, no invasion to the intraspinal canal or great vessels, and parental consent to participate.
  • Patients who did not meet observation criteria underwent surgery or mild chemotherapy according to the location of the tumor.
  • If patients met observation criteria after chemotherapy, surgical intervention was no longer performed.
  • Tumors regressed in 7 patients (mean follow-up period 36.3 months) with corresponding decreases in VMA and HVA levels (group A).
  • Four patients underwent primary surgery (group C), and 19 patients had chemotherapy initially.
  • Fourteen patients met observation criteria after chemotherapy and two are still having chemotherapy (group D).
  • Three patients required surgery due to insufficient regression of their tumors (group E).
  • Fourteen subjects in group D had marked decreases in VMA and HVA levels and tumor size (mean follow-up period 29.1 months), and tumors were not detected using imaging techniques in 8 patients.
  • There was no evidence of unfavorable prognosis in any of the 33 subjects, although 1 patient who underwent primary surgery had a vanishing kidney 1 year later and 1 patient had multiple bony metastases after complete resection of tumor, which was treated by chemotherapy.
  • Until the real significance of mass screening for neuroblastoma as a public health measure is confirmed, observation with careful follow-up should be adopted more extensively because it has a favorable outcome in many cases, and is associated with minimal therapeutic complications.
  • [MeSH-minor] Adrenal Gland Neoplasms / pathology. Adrenal Gland Neoplasms / prevention & control. Adrenal Gland Neoplasms / surgery. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Creatinine / urine. Follow-Up Studies. Homovanillic Acid / urine. Hospitals, Pediatric. Humans. Infant. Japan. Neoplasm Regression, Spontaneous. Neoplasm Staging. Parental Consent. Prognosis. Proto-Oncogene Proteins c-myc / analysis. Retroperitoneal Neoplasms / pathology. Retroperitoneal Neoplasms / prevention & control. Retroperitoneal Neoplasms / urine. Treatment Outcome. Vanilmandelic Acid / urine

  • Genetic Alliance. consumer health - Neuroblastoma.
  • MedlinePlus Health Information. consumer health - Neuroblastoma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lancet. 1996 Dec 21-28;348(9043):1682-7 [8973429.001]
  • [Cites] Lancet. 1984 Aug 4;2(8397):271-3 [6146820.001]
  • [Cites] Cancer. 1987 Aug 1;60(3):433-6 [3594383.001]
  • [Cites] Cancer. 1992 Sep 15;70(6):1625-33 [1516016.001]
  • [Cites] N Engl J Med. 2002 Apr 4;346(14):1041-6 [11932470.001]
  • [Cites] J Clin Oncol. 1995 Aug;13(8):2033-8 [7636545.001]
  • [Cites] Cancer. 1971 Feb;27(2):374-8 [5100400.001]
  • [Cites] N Engl J Med. 2002 Apr 4;346(14):1047-53 [11932471.001]
  • [Cites] J Pediatr Surg. 2001 Nov;36(11):1633-6 [11685689.001]
  • [Cites] J Pediatr. 1991 Aug;119(2):237-41 [1861208.001]
  • [Cites] J Clin Oncol. 1995 Apr;13(4):884-93 [7707115.001]
  • [Cites] Eur J Cancer. 1995;31A(4):565-8 [7576969.001]
  • [Cites] J Pediatr Surg. 1998 Nov;33(11):1674-8 [9856893.001]
  • [Cites] Med Pediatr Oncol. 2001 Jan;36(1):157-9 [11464873.001]
  • [Cites] J Clin Oncol. 2000 Aug;18(16):3012-7 [10944135.001]
  • [Cites] J Clin Oncol. 1998 Apr;16(4):1265-9 [9552024.001]
  • [Cites] J Clin Oncol. 1990 Dec;8(12):2005-13 [2230892.001]
  • [Cites] J Pediatr Surg. 2002 Jul;37(7):949-54 [12077747.001]
  • [Cites] Cancer. 2001 Jul 15;92(2):349-53 [11466689.001]
  • (PMID = 14689211.001).
  • [ISSN] 0179-0358
  • [Journal-full-title] Pediatric surgery international
  • [ISO-abbreviation] Pediatr. Surg. Int.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Proto-Oncogene Proteins c-myc; 55-10-7 / Vanilmandelic Acid; AYI8EX34EU / Creatinine; X77S6GMS36 / Homovanillic Acid
  •  go-up   go-down


25. Naguib SF, El Haddad A, El Badawy SA, Zaghloul AS: Multidisciplinary approach to wilms' tumor: a retrospective analytical study of 53 patients. J Egypt Natl Canc Inst; 2008 Dec;20(4):410-23

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • AIM OF THE WORK: The aim of this work was to assess the epidemiologic aspects, clinico-pathological features and the results of multidisciplinary treatment of Wilms' tumor (WT) in pediatric patients treated at the National Cancer Institute (NCI), Cairo University, between January 2002 and December 2004.
  • Neoadjuvant chemotherapy was given to patients suffering from poor general condition, extensive tumor thrombus in the renal vein, irresectable and bilateral (stage V) nephroblastoma.
  • Otherwise, up-front nephrectomy was the standard therapeutic approach in this study.
  • Tumors were located in the left kidney in 52.8%, right kidney in 41.5% and bilaterally in only 5.7% of the cases.
  • Stage I and III were the most common (29.4% each), followed by stage II and IV (17.7% each), and finally by stage V (5.9%).
  • Neoadjuvant chemotherapy was given to 27 cases while up-front nephrectomy was undertaken in 26 cases.
  • Intra-operative spillage occurred in 12% of patients who had preoperative chemotherapy and 31% of those who had upfront nephrectomy.
  • Complete remission (CR) was achieved in 74%, while death during neoadjuvant therapy took place in 4% of the cases.
  • Disease progression during treatment was noticed in 8%.
  • These patients were all treated with radio- and chemotherapy.
  • Therapy-related complications were mainly related to chemotherapy in 49% of patients and surgery in 5.9%.
  • Regional lymph node biopsy and accurate marking of residual disease are essential components of surgical treatment and heroic surgical attempts are unnecessary.
  • Neoadjuvant chemotherapy, which is still a fertile source of debate, could possibly help to avoid excessive post-operative radiotherapy and its potential complications.
  • Tumor stage and age of patient were found to affect the results of treatment of Wilms' tumor; but the only statistically significant determinant of prognosis was histologic differentiation.
  • Finally, further studies including molecular markers are needed to augment therapy for the blastemal predominance subtype or for favorable histology associated with loss of heterozygosity (LOA) at chromosomes 1p and 16q aiming at improved survival.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20571600.001).
  • [ISSN] 1110-0362
  • [Journal-full-title] Journal of the Egyptian National Cancer Institute
  • [ISO-abbreviation] J Egypt Natl Canc Inst
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Egypt
  •  go-up   go-down


26. Fernández-Pineda I, Cabello Laureano R, Fernández-Hurtado MA, Granero Cendón R, Tuduri Limousín I, Morcillo Azcárate J, Aspiazu Salinas D, García Vallés C, De Agustín Asensio JC: [Surgical management of bilateral Wilms' tumor: our experience with 18 cases]. Cir Pediatr; 2009 Oct;22(4):186-8
MedlinePlus Health Information. consumer health - Wilms Tumor.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Manejo quirúrgico del tumor de Wilms bilateral: nuestra experiencia con 18 casos.
  • METHODS: We have reviewed the medical records of 18 patients diagnosed of bilateral Wilms' tumor between 1971 and 2007, evaluating age, sex, clinical situation, imaging studies, histology, treatment, complications and follow-up.
  • RESULTS: 65% of patients with synchronous Wilms' tumor was stage I-II, 30% stage III and 5% stage IV.
  • 100% of patients with metachronous Wilms' tumor was stage I-II.
  • All the tumors had favourable histology.
  • CONCLUSIONS: Preoperative chemotherapy allows a conservative surgical resection with a high overall survival (80-90%).
  • Individualized surgical treatment offers a conservative surgical resection with a lower incidence of long-term renal failure.
  • [MeSH-major] Kidney Neoplasms / surgery. Neoplasms, Multiple Primary / surgery. Wilms Tumor / surgery

  • Genetic Alliance. consumer health - Wilms' tumor.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20405651.001).
  • [ISSN] 0214-1221
  • [Journal-full-title] Cirugía pediátrica : organo oficial de la Sociedad Española de Cirugía Pediátrica
  • [ISO-abbreviation] Cir Pediatr
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


27. Falardeau P, Champagne P, Poyet P, Hariton C, Dupont E: Neovastat, a naturally occurring multifunctional antiangiogenic drug, in phase III clinical trials. Semin Oncol; 2001 Dec;28(6):620-5
MedlinePlus Health Information. consumer health - Multiple Myeloma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neovastat, a naturally occurring multifunctional antiangiogenic drug, in phase III clinical trials.
  • Recent studies have indicated that bone marrow angiogenesis is increased in multiple myeloma, suggesting that treatment with an antiangiogenic agent might be useful.
  • Among the new antiangiogenic drugs in development, Neovastat (AE-941; Aeterna Laboratories, Quebec City, Canada) can be classified as a naturally occurring multifunctional antiangiogenic agent.
  • Furthermore, no treatment-related mortality or loss of body weight was observed.
  • In the oncology field, 482 patients have received Neovastat, of which 146 with solid tumors were exposed to the drug for more than 6 months.
  • A phase III double-blind placebo-controlled study is being conducted to evaluate the efficacy of Neovastat in addition to induction chemotherapy/radiotherapy combined modality treatment in patients with unresectable non-small cell lung cancer stage IIIA and IIIB.
  • Neovastat efficacy is also being evaluated in a registration phase II trial in patients with early relapse or refractory multiple myeloma.
  • [MeSH-major] Angiogenesis Inhibitors / therapeutic use. Bone Marrow / blood supply. Bone Marrow / drug effects. Multiple Myeloma / drug therapy. Tissue Extracts / therapeutic use
  • [MeSH-minor] Animals. Cartilage / chemistry. Clinical Trials as Topic. Drug Screening Assays, Antitumor. Humans. Kidney Neoplasms / drug therapy. Lung Neoplasms / drug therapy. Neoplasm Metastasis / drug therapy. Neovascularization, Pathologic. Sharks

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2001 by W.B. Saunders Company.
  • (PMID = 11740820.001).
  • [ISSN] 0093-7754
  • [Journal-full-title] Seminars in oncology
  • [ISO-abbreviation] Semin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Tissue Extracts; 0 / shark cartilage extract
  • [Number-of-references] 42
  •  go-up   go-down


28. Pedersen MØ, Larsen A, Stoltenberg M, Penkowa M: The role of metallothionein in oncogenesis and cancer prognosis. Prog Histochem Cytochem; 2009;44(1):29-64
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The antiapoptotic, antioxidant, proliferative, and angiogenic effects of metallothionein (MT)-I+II has resulted in increased focus on their role in oncogenesis, tumor progression, therapy response, and patient prognosis.
  • Studies have reported increased expression of MT-I+II mRNA and protein in various human cancers; such as breast, kidney, lung, nasopharynx, ovary, prostate, salivary gland, testes, urinary bladder, cervical, endometrial, skin carcinoma, melanoma, acute lymphoblastic leukemia (ALL), and pancreatic cancers, where MT-I+II expression is sometimes correlated to higher tumor grade/stage, chemotherapy/radiation resistance, and poor prognosis.
  • However, MT-I+II are downregulated in other types of tumors (e.g. hepatocellular, gastric, colorectal, central nervous system (CNS), and thyroid cancers) where MT-I+II is either inversely correlated or unrelated to mortality.
  • Large discrepancies exist between different tumor types, and no distinct and reliable association exists between MT-I+II expression in tumor tissues and prognosis and therapy resistance.
  • Furthermore, a parallel has been drawn between MT-I+II expression as a potential marker for prognosis, and MT-I+II's role as oncogenic factors, without any direct evidence supporting such a parallel.
  • This review aims at discussing the role of MT-I+II both as a prognostic marker for survival and therapy response, as well as for the hypothesized role of MT-I+II as causal oncogenes.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19348910.001).
  • [ISSN] 0079-6336
  • [Journal-full-title] Progress in histochemistry and cytochemistry
  • [ISO-abbreviation] Prog Histochem Cytochem
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 9038-94-2 / Metallothionein
  • [Number-of-references] 203
  •  go-up   go-down


29. Owens CM, Veys PA, Pritchard J, Levitt G, Imeson J, Dicks-Mireaux C: Role of chest computed tomography at diagnosis in the management of Wilms' tumor: a study by the United Kingdom Children's Cancer Study Group. J Clin Oncol; 2002 Jun 15;20(12):2768-73
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of chest computed tomography at diagnosis in the management of Wilms' tumor: a study by the United Kingdom Children's Cancer Study Group.
  • PURPOSE: This study sought to determine whether the identification of minimal pulmonary metastatic disease by chest computed tomography (CT) performed at diagnosis in patients with Wilms' tumor and normal chest x-rays (CXR) could predict a subgroup of children at increased risk of pulmonary relapse.
  • After surgery, children with stage I Wilms' tumor received single-agent chemotherapy (vincristine), whereas children with stages II, III, and bilateral Wilms' tumor received combination chemotherapy.
  • Most children with stage III tumors were also treated with abdominal radiotherapy (20 Gy).
  • When only stage I patients were analyzed, there was a significant difference between the pulmonary relapse rate of 43% (three of seven) in the CT-positive group and 10% (five of 48) in the CT-negative group (P =.02).
  • Four of eight patients with stage I disease with pulmonary relapse died.
  • CONCLUSION: CT seemed to identify a subgroup of stage I patients who were at increased risk of pulmonary relapse.
  • These children had received only single-agent chemotherapy.
  • A prospective randomized trial is needed to clarify whether these children would benefit from combination chemotherapy.
  • [MeSH-major] Kidney Neoplasms / pathology. Lung Neoplasms / radiography. Lung Neoplasms / secondary. Neoplasm Staging. Tomography, X-Ray Computed. Wilms Tumor / radiography. Wilms Tumor / secondary
  • [MeSH-minor] Antineoplastic Agents, Phytogenic / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Child. Child, Preschool. Female. Humans. Infant. Infant, Newborn. Male. Predictive Value of Tests. Prognosis. Recurrence. Retrospective Studies. Risk Factors. Vincristine / therapeutic use

  • Genetic Alliance. consumer health - Wilms' tumor.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Wilms Tumor.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Clin Oncol. 2002 Jun 15;20(12):2763-4 [12065550.001]
  • (PMID = 12065552.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 5J49Q6B70F / Vincristine
  •  go-up   go-down


30. Monge AH, Pineda RP, del Rocio Estrada Hernandez M, Juárez EG, García JC: [Fallopian tube primary invasive adenocarcinoma associated with acute inflammatory pelvic disease. Case report and literature review]. Ginecol Obstet Mex; 2008 Feb;76(2):118-24
Hazardous Substances Data Bank. CLINDAMYCIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Adenocarcinoma invasor primario de trompa de falopio concomitante con enfermedad pélvica inflamatoria aguda. Comunicación de un caso y revisión de la bibliografía.
  • The primary fallopian tube invader adenocarcinoma is a preoperative diagnosis rarely reported in the literature, because is the most uncommon of all gynecological tumors, with prevalence from 0.3 to 1.8%.
  • The treatment is predominantly surgical, as that of epithelial ovarian carcinoma, and consists of an intraperitoneal washing, total abdominal hysterectomy with bilateral salpingo-oophorectomy and a proper staging.
  • In some cases, as the persistence or recurrence of illness, it can be necessary adjuvant chemotherapy.
  • In some patients in early stage I or II with low risk, the complete staging could not be necessary.
  • There is controversy about administration criteria of adjuvant treatment, since there is not evidence of survival increase related to its use.
  • The five years survival rate was 64% for stage I, 42% for stage II, 32% for stage III, and 17% for stage IV.
  • [MeSH-minor] Abdomen, Acute / etiology. Acute Kidney Injury / etiology. Anti-Bacterial Agents / therapeutic use. Anuria / etiology. Ceftriaxone / therapeutic use. Clindamycin / therapeutic use. Female. Humans. Hysterectomy. Middle Aged. Ovariectomy. Peritonitis / drug therapy. Peritonitis / etiology

  • MedlinePlus Health Information. consumer health - Pelvic Inflammatory Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18798405.001).
  • [ISSN] 0300-9041
  • [Journal-full-title] Ginecología y obstetricia de México
  • [ISO-abbreviation] Ginecol Obstet Mex
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Mexico
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; 3U02EL437C / Clindamycin; 75J73V1629 / Ceftriaxone
  • [Number-of-references] 10
  •  go-up   go-down


31. Meng S, Jiamei L: Management of tongue cancer in the patient who is systemically immunosuppressed: a preliminary report. Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2000 Dec;90(6):689-93
MedlinePlus Health Information. consumer health - Kidney Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: Renal transplantation is being improved, and life expectancy for patients with transplanted kidneys is being prolonged, but the incidence of malignant tumors in other body organs or tissues is increasing progressively.
  • All diagnoses were confirmed microscopically to be squamous cell carcinomas stage I to II.
  • RESULTS: The doses of immunosuppressive agents were decreased, and two patients accepted surgery, chemotherapy, and radiotherapy.
  • CONCLUSION: Patients who have lingual cancer develop after renal transplantation have received long-term immunosuppressive therapy.
  • (1) Besides regular evaluation after renal transplantation, physical examination and biopsy of suspicious oral lesions are necessary because of the possibility of postrenal malignancy. (2) Surgery, along with chemotherapy and radiotherapy, is the main treatment of lingual cancer after renal transplantation. (3) The lingual tumor should be comprehensively treated despite the poor immune state of the body, or tumor recurrence can accelerate and metastases can occur. (4) Treating cancer thoroughly and maintaining the function of the transplanted kidney can decrease the patient's immune status.
  • [MeSH-major] Carcinoma, Squamous Cell / therapy. Immunocompromised Host. Kidney Transplantation / immunology. Tongue Neoplasms / therapy
  • [MeSH-minor] Adult. Chemotherapy, Adjuvant. Clinical Protocols. Glossectomy. Humans. Immunosuppressive Agents / administration & dosage. Male. Middle Aged. Radiotherapy, Adjuvant. Treatment Outcome

  • Genetic Alliance. consumer health - Tongue cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11113812.001).
  • [ISSN] 1079-2104
  • [Journal-full-title] Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics
  • [ISO-abbreviation] Oral Surg Oral Med Oral Pathol Oral Radiol Endod
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Immunosuppressive Agents
  •  go-up   go-down


32. Brisse HJ, Schleiermacher G, Sarnacki S, Helfre S, Philippe-Chomette P, Boccon-Gibod L, Peuchmaur M, Mosseri V, Aigrain Y, Neuenschwander S: Preoperative Wilms tumor rupture: a retrospective study of 57 patients. Cancer; 2008 Jul 1;113(1):202-13
MedlinePlus Health Information. consumer health - Wilms Tumor.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: According to current International Society of Pediatric Oncology (SIOP) Wilms recommendations, all preoperative tumor ruptures should be classified as stage IIIc.
  • METHODS: The authors performed a retrospective analysis of 57 children with clinical and/or radiologic (computed tomography [CT]) signs of preoperative tumor rupture of a series of 250 patients enrolled in Wilms SIOP protocols at their institution.
  • Surgery was performed after chemotherapy in 55 of 57 patients.
  • Peritoneal disease recurrence occurred in 3 of 57 patients, including 2 patients with stage III tumors who had initial intraperitoneal rupture and 1 patient with a stage I tumor.
  • Among the 48 patients who had radiologic signs of retroperitoneal-only rupture, the final pathologic stage was stage III in 22 patients, stage II in 9 patients, and stage I in 17 patients, and no abdominal disease recurrence was observed, although only 23 of 48 patients received flank radiotherapy.
  • In contrast, patients who have radiologic signs of localized retroperitoneal-only rupture at diagnosis most likely should not be upstaged, and their treatment may be determined according to pathologic stage only.
  • [MeSH-major] Kidney Neoplasms / complications. Rupture, Spontaneous / complications. Wilms Tumor / complications
  • [MeSH-minor] Chemotherapy, Adjuvant. Child, Preschool. Combined Modality Therapy. Disease-Free Survival. Female. Humans. Infant. Male. Neoadjuvant Therapy. Neoplasm Recurrence, Local. Preoperative Care. Retrospective Studies. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (Copyright) 2008 American Cancer Society.
  • (PMID = 18457331.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


33. Hung IJ, Chang WH, Yang CP, Jaing TH, Liang DC, Lin KH, Lin DT, Hsiao CC, Hsieh YL, Chen JS, Chang TT, Peng CT, Shu SG, Lin MT, Chen BW, Lin KS, Taiwan Pediatric Oncology Group: Epidemiology, clinical features and treatment outcome of Wilms' tumor in Taiwan: a report from Taiwan Pediatric Oncology Group. J Formos Med Assoc; 2004 Feb;103(2):104-11
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epidemiology, clinical features and treatment outcome of Wilms' tumor in Taiwan: a report from Taiwan Pediatric Oncology Group.
  • Patients received individualized multimodality treatment based upon the histology of the tumor and clinicopathologic stage.
  • The treatment included surgery, radiotherapy and 2-, 3-, and 4-agent active chemotherapeutic agents.
  • Seventy patients were eligible for analysis of treatment outcome.
  • Patients were divided into various subgroups according to the chemotherapy regimen used, tumor stage, age at diagnosis, gender, and tumor weight.
  • All bilateral tumors occurred in females.
  • The stage distribution was: I, 43.2%; II, 19.3%; III, 23.9%; IV, 6.8%; and V, 6.8%.
  • The median follow-up time was 89.1 months (range, 1.8 to 128.1 months).
  • The 5-year PFS rate was 0.7841 (SE, 0.0494; 53 of 70 patients) and the 5-year OS rate was 0.886 (SE, 0.038; 63 of 70 patients).
  • CONCLUSIONS: This study evaluated the epidemiological characteristics, clinical features, multimodality therapy regimens, and treatment outcome of WT in Taiwan.

  • Genetic Alliance. consumer health - Wilms' tumor.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • MedlinePlus Health Information. consumer health - Wilms Tumor.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15083240.001).
  • [ISSN] 0929-6646
  • [Journal-full-title] Journal of the Formosan Medical Association = Taiwan yi zhi
  • [ISO-abbreviation] J. Formos. Med. Assoc.
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Singapore
  •  go-up   go-down


34. Rosner GL, Stadler W, Ratain MJ: Randomized discontinuation design: application to cytostatic antineoplastic agents. J Clin Oncol; 2002 Nov 15;20(22):4478-84
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: Propose a phase II study design to evaluate the activity of a putative cytostatic agent, acknowledging heterogeneity of tumor growth rates in the population of patients.
  • METHODS: In the setting of renal cell carcinoma, some patients' tumors will grow slowly naturally.
  • We propose a randomized discontinuation design that initially treats all patients with the study agent (stage 1) and then randomizes in a double-blind fashion to continuing therapy or placebo only those patients whose disease is stable (stage 2).
  • This design allows the investigators to determine if apparent slow tumor growth is attributable to the drug or to selection of patients with naturally slow-growing tumors.
  • Because the two randomly assigned treatment groups each comprise patients with apparently slow growing tumors, any difference between the groups in disease progression after randomization is more likely a result of the study drug and less likely a result of imbalance with respect to tumor growth rates.
  • Stopping rules during the initial open-label stage and the subsequent randomized trial stage allow one to reduce the overall sample size.
  • CONCLUSION: The randomized discontinuation design is a feasible alternative phase II study design for determining activity of possibly cytostatic anticancer agents.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Carcinoma, Renal Cell / drug therapy. Carcinoma, Renal Cell / pathology. Kidney Neoplasms / drug therapy. Kidney Neoplasms / pathology. Research Design
  • [MeSH-minor] Disease Progression. Double-Blind Method. Drug Administration Schedule. Humans

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12431972.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA33601; United States / NCI NIH HHS / CA / CA44691
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


35. Rini BI, Weinberg V, Dunlap S, Elchinoff A, Yu N, Bok R, Simko J, Small EJ: Maximal COX-2 immunostaining and clinical response to celecoxib and interferon alpha therapy in metastatic renal cell carcinoma. Cancer; 2006 Feb 1;106(3):566-75
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Maximal COX-2 immunostaining and clinical response to celecoxib and interferon alpha therapy in metastatic renal cell carcinoma.
  • COX-2 is expressed in the majority of renal cell carcinoma (RCC) tumors and correlates with stage, grade, and microvessel density.
  • Based on potential additive or synergistic antitumor effects, interferon-alpha (IFNalpha) and celecoxib, an oral COX-2 inhibitor, were given to metastatic RCC patients in a Phase II trial.
  • The observed median time to disease progression (TTP) for the entire cohort was 3.3 months.
  • Therapy was well tolerated without cardiac or other notable toxicity.
  • Further investigation of this combination in 3+ COX-2-overexpressing RCC tumors is warranted.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carcinoma, Renal Cell / drug therapy. Cyclooxygenase 2 / biosynthesis. Cyclooxygenase Inhibitors / therapeutic use. Interferon-alpha / therapeutic use. Kidney Neoplasms / drug therapy. Pyrazoles / therapeutic use. Sulfonamides / therapeutic use
  • [MeSH-minor] Administration, Oral. Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / analysis. Celecoxib. Disease Progression. Female. Fibroblast Growth Factor 2 / analysis. Humans. Immunohistochemistry. Male. Middle Aged. Predictive Value of Tests. Prognosis. Treatment Outcome. Vascular Endothelial Growth Factor A / analysis

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CELECOXIB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2005 American Cancer Society.
  • (PMID = 16369983.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Biomarkers, Tumor; 0 / Cyclooxygenase Inhibitors; 0 / Interferon-alpha; 0 / Pyrazoles; 0 / Sulfonamides; 0 / Vascular Endothelial Growth Factor A; 103107-01-3 / Fibroblast Growth Factor 2; EC 1.14.99.1 / Cyclooxygenase 2; JCX84Q7J1L / Celecoxib
  •  go-up   go-down


36. Jiang YG, Chen JH, Jiang R, Hang G, Wang GH, Wang D, Li FC, Liu H, Shi CJ, Wu HJ, Yuan YG: [Testicular tumor in Mongolian men (report of 35 cases)]. Zhonghua Nan Ke Xue; 2006 May;12(5):397-400
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To improve the diagnosis, therapy and prognosis of testicular tumor in Mongolian men.
  • METHODS: A retrospective review of 35 cases of testicular tumors in Mongolian men from seven medical centers dated from 1990 to 2004 was performed.
  • Regarding stage, 22, 2, and 5 of 29 germ cell tumors were seen initially as stage I, II, and III, respectively.
  • Combined therapy, including radical orchiectomy, radiotherapy and chemotherapy, were taken.
  • CONCLUSION: In this article, the rate of seminoma to germ cell tumors is higher than that of general population.
  • Better public awareness regarding testicular tumor in this population, advances in diagnosis and therapy will help to improve therapeutic effectiveness and prognosis.
  • [MeSH-major] Testicular Neoplasms / diagnosis. Testicular Neoplasms / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child, Preschool. Combined Modality Therapy. Follow-Up Studies. Humans. Infant. Male. Middle Aged. Prognosis. Retrospective Studies. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16755865.001).
  • [ISSN] 1009-3591
  • [Journal-full-title] Zhonghua nan ke xue = National journal of andrology
  • [ISO-abbreviation] Zhonghua Nan Ke Xue
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Multicenter Study
  • [Publication-country] China
  •  go-up   go-down


37. Dozić J, Bogdanović J: [Current diagnostic and therapeutic approaches to invasive bladder cancer]. Med Pregl; 2005 Sep-Oct;58(9-10):465-71
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Current diagnostic and therapeutic approaches to invasive bladder cancer].
  • INTRODUCTION: Bladder cancer is the second most common urological cancer (after prostate cancer, and before kidney and testicular tumors).
  • T2 stage is underestimated in 40-50% of cases, whereas lymph nodes are positive in 10% of cases in T1 stage of the disease.
  • The aim of this study was to present modern diagnostic-therapeutic procedures, which are being used in multimodal treatment of invasive bladder tumors (surgery, chemotherapy, radiotherapy), indications for their use, and treatment outcome in regard to the stage of the disease.
  • PATHOLOGICAL DIAGNOSIS: Pathological diagnosis is a key factor for correct and on-time treatment.
  • TREATMENT OF BLADDER CANCER: Treatment of bladder tumors is multimodal, multidisciplinary and includes surgery, chemotherapy and radiotherapy.
  • In regard to indications and established protocols, surgery is partial, simple or radical cystectomy, followed by different types of urine derivation (wet stoma--Bricker's ileal conduit, dry stoma--Kock pouch, ureterosigmoidostomy--Mainz pouch II, or orthotopic ileal bladder substitution).
  • The use of new operative procedures can be done only during the early stage of the disease.
  • CONCLUSION: Using new diagnostic equipment, up-to date therapeutic procedures, bladder cancer becomes a curable disease (depending on the stage of the disease) with high survival rate and better quality of life.
  • [MeSH-major] Urinary Bladder Neoplasms / diagnosis. Urinary Bladder Neoplasms / therapy


38. Garcia JA, Hutson TE, Elson P, Cowey CL, Gilligan T, Nemec C, Dreicer R, Bukowski RM, Rini BI: Sorafenib in patients with metastatic renal cell carcinoma refractory to either sunitinib or bevacizumab. Cancer; 2010 Dec 1;116(23):5383-90
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Bevacizumab and sunitinib are standard initial therapy in metastatic renal cell carcinoma (mRCC).
  • METHODS: Metastatic RCC patients with Response Evaluation Criteria in Solid Tumors (RECIST)-defined disease progression (PD) after treatment with either bevacizumab or sunitinib received twice daily 400 mg of sorafenib in a multicenter, prospective phase 2 study.
  • A 2-stage accrual design was used to test the alternative hypothesis that the tumor burden reduction rate was >20% versus <5%.
  • There was no association of PFS and tumor shrinkage with response to prior therapy.
  • Most treatment-related adverse events were of mild-to-moderate intensity, and included fatigue, hypertension, diarrhea, and palmoplantar erythrodysesthesia (PPE).
  • Modest clinical activity was observed supporting current practice patterns of sequential vascular endothelial growth factor-targeted therapy in mRCC.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Benzenesulfonates / therapeutic use. Carcinoma, Renal Cell / drug therapy. Drug Resistance, Neoplasm. Kidney Neoplasms / drug therapy. Pyridines / therapeutic use. Receptors, Vascular Endothelial Growth Factor / antagonists & inhibitors
  • [MeSH-minor] Aged. Antibodies, Monoclonal / therapeutic use. Antibodies, Monoclonal, Humanized. Bevacizumab. Female. Humans. Indoles / therapeutic use. Male. Middle Aged. Neoplasm Metastasis. Niacinamide / analogs & derivatives. Phenylurea Compounds. Pyrroles / therapeutic use

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. NICOTINAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 American Cancer Society.
  • (PMID = 20806321.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antineoplastic Agents; 0 / Benzenesulfonates; 0 / Indoles; 0 / Phenylurea Compounds; 0 / Pyridines; 0 / Pyrroles; 0 / sunitinib; 25X51I8RD4 / Niacinamide; 2S9ZZM9Q9V / Bevacizumab; 9ZOQ3TZI87 / sorafenib; EC 2.7.10.1 / Receptors, Vascular Endothelial Growth Factor
  •  go-up   go-down






Advertisement